Acute phase reactant, Pentraxin 3, as a novel marker for the diagnosis of rheumatoid arthritis.
Pentraxins are a group of highly conserved acute-phase reactant proteins and play crucial role as modulators of inflammatory processes. Pentraxin 3 (PTX3) is primarily produced and released by vascular cell wall, hence, we attempt to establish the role of PTX3 as a biomarker for Rheumatoid Arthritis (RA) compared to CRP. Thirty patients having active RA as cases and 30 osteoarthritis (OA) patients as controls were recruited. Paired serum and synovial fluid samples were analysed for concentrations of both PTX3 and CRP by using high sensitivity ELISA kit and ROC curve was plotted. Concentrations of PTX3 and CRP were significantly higher in RA patient serum (p < 0.0001) as well as in synovial fluid (p < 0.0001) and correlated with disease severity. Upon correlation analysis, positive correlation was found between serum and synovial fluid concentrations of PTX3 and CRP. The diagnostic potential of PTX3 was observed in synovial fluid while combination of PTX3 and CRP showed better sensitivity in serum. PTX3 found to be sensitive non-invasive indicator of clinical arthritic activity in RA patients when compared to traditional markers like CRP. Combination of PTX3 and CRP could serve as better differential diagnostic markers for RA after validation in larger patient cohort.